Logo image of HCWB

HCW BIOLOGICS INC (HCWB) Stock Fundamental Analysis

USA - NASDAQ:HCWB - US40423R2040 - Common Stock

3.99 USD
-0.03 (-0.75%)
Last: 10/17/2025, 8:17:58 PM
3.9 USD
-0.09 (-2.26%)
After Hours: 10/17/2025, 8:17:58 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to HCWB. HCWB was compared to 536 industry peers in the Biotechnology industry. Both the profitability and financial health of HCWB have multiple concerns. HCWB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

HCWB had negative earnings in the past year.
HCWB had a negative operating cash flow in the past year.
In the past 5 years HCWB always reported negative net income.
In the past 5 years HCWB always reported negative operating cash flow.
HCWB Yearly Net Income VS EBIT VS OCF VS FCFHCWB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

The Return On Assets of HCWB (-74.56%) is worse than 65.11% of its industry peers.
Industry RankSector Rank
ROA -74.56%
ROE N/A
ROIC N/A
ROA(3y)-72.93%
ROA(5y)-57.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HCWB Yearly ROA, ROE, ROICHCWB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

HCWB's Gross Margin of 20.00% is fine compared to the rest of the industry. HCWB outperforms 72.57% of its industry peers.
The Profit Margin and Operating Margin are not available for HCWB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HCWB Yearly Profit, Operating, Gross MarginsHCWB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

0

2. Health

2.1 Basic Checks

HCWB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HCWB has more shares outstanding
Compared to 5 years ago, HCWB has more shares outstanding
Compared to 1 year ago, HCWB has a worse debt to assets ratio.
HCWB Yearly Shares OutstandingHCWB Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
HCWB Yearly Total Debt VS Total AssetsHCWB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -7.15, we must say that HCWB is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -7.15, HCWB is doing worse than 67.54% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.15
ROIC/WACCN/A
WACC9.01%
HCWB Yearly LT Debt VS Equity VS FCFHCWB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.11 indicates that HCWB may have some problems paying its short term obligations.
HCWB's Current ratio of 0.11 is on the low side compared to the rest of the industry. HCWB is outperformed by 97.01% of its industry peers.
A Quick Ratio of 0.11 indicates that HCWB may have some problems paying its short term obligations.
HCWB has a Quick ratio of 0.11. This is amonst the worse of the industry: HCWB underperforms 96.83% of its industry peers.
Industry RankSector Rank
Current Ratio 0.11
Quick Ratio 0.11
HCWB Yearly Current Assets VS Current LiabilitesHCWB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

HCWB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 61.03%, which is quite impressive.
The Revenue for HCWB has decreased by -78.77% in the past year. This is quite bad
EPS 1Y (TTM)61.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.21%
Revenue 1Y (TTM)-78.77%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-98.87%

3.2 Future

Based on estimates for the next years, HCWB will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.62% on average per year.
Based on estimates for the next years, HCWB will show a very strong growth in Revenue. The Revenue will grow by 109.56% on average per year.
EPS Next Y79.82%
EPS Next 2Y33.43%
EPS Next 3Y23.44%
EPS Next 5Y13.62%
Revenue Next Year-23.55%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y109.56%

3.3 Evolution

HCWB Yearly Revenue VS EstimatesHCWB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2022 2023 2024 2025 2028 2029 2030 200M 400M 600M
HCWB Yearly EPS VS EstimatesHCWB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

HCWB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year HCWB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HCWB Price Earnings VS Forward Price EarningsHCWB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HCWB Per share dataHCWB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

A more expensive valuation may be justified as HCWB's earnings are expected to grow with 23.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.43%
EPS Next 3Y23.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HCWB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HCW BIOLOGICS INC

NASDAQ:HCWB (10/17/2025, 8:17:58 PM)

After market: 3.9 -0.09 (-2.26%)

3.99

-0.03 (-0.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-18 2025-08-18/dmh
Earnings (Next)N/A N/A
Inst Owners1%
Inst Owner Change0%
Ins Owners27.57%
Ins Owner Change18.01%
Market Cap8.58M
Analysts82.86
Price Target35.7 (794.74%)
Short Float %22.47%
Short Ratio0.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.1%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.3
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-16.07
EYN/A
EPS(NY)-5.11
Fwd EYN/A
FCF(TTM)-5.91
FCFYN/A
OCF(TTM)-5.84
OCFYN/A
SpS0.39
BVpS-0.02
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -74.56%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20%
FCFM N/A
ROA(3y)-72.93%
ROA(5y)-57.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.94%
Cap/Sales 18.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.11
Quick Ratio 0.11
Altman-Z -7.15
F-Score4
WACC9.01%
ROIC/WACCN/A
Cap/Depr(3y)665.42%
Cap/Depr(5y)407.44%
Cap/Sales(3y)127.14%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.21%
EPS Next Y79.82%
EPS Next 2Y33.43%
EPS Next 3Y23.44%
EPS Next 5Y13.62%
Revenue 1Y (TTM)-78.77%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-98.87%
Revenue Next Year-23.55%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y109.56%
EBIT growth 1Y70.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y59.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.41%
OCF growth 3YN/A
OCF growth 5YN/A